

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_85192
Title of the Manuscript:	A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Radiotherapy for NSCLC
Type of the Article	Study Protocol

General guideline for Peer Review process:

This journal’s peer review policy states that **NO** manuscript should be rejected only on the basis of ‘**lack of Novelty**’, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journaljpri.com/index.php/JPRI/editorial-policy>)

PART 1: Review Comments

	Reviewer’s comment	Author’s comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	Abstract : please use the term “Karnofsky score” rather than KPS in the background	agreed and modified <i>the manuscript</i>
Minor REVISION comments		
Optional/General comments	Good written manuscript	

PART 2:

	Reviewer’s comment	Author’s comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<u><i>(If yes, Kindly please write down the ethical issues here in details)</i></u>	1. This trial was approved by the research ethics committee of the second hospital of Hebei Medical University (2018-R099). 2. Radiotherapy is the standard treatment for lung cancer.